NYSE:NVO

Novo Nordisk A/S News Headlines

$95.42
+2.30 (+2.47 %)
(As of 08/4/2021 10:33 AM ET)
Add
Compare
Today's Range
$93.58
$96.33
50-Day Range
$78.82
$93.12
52-Week Range
$63.22
$93.34
Volume44,803 shs
Average Volume905,389 shs
Market Capitalization$224.70 billion
P/E Ratio33.13
Dividend Yield1.43%
Beta0.42

Novo Nordisk A/S (NYSE NVO) News Headlines Today

SourceHeadline
3 European Stocks to Buy for International Exposure (NVO)3 European Stocks to Buy for International Exposure (NVO)
marketbeat.com - May 25 at 8:05 PM
Novo Nordisk A/S (NYSE:NVO) Rating Reiterated by Deutsche Bank AktiengesellschaftNovo Nordisk A/S (NYSE:NVO) Rating Reiterated by Deutsche Bank Aktiengesellschaft
americanbankingnews.com - August 3 at 5:04 PM
Novo Nordisk A/S (NYSE:NVO) Reaches New 52-Week High at $93.10Novo Nordisk A/S (NYSE:NVO) Reaches New 52-Week High at $93.10
americanbankingnews.com - August 3 at 10:46 AM
Novo Nordisk A/S Common Stock (NVO)Novo Nordisk A/S Common Stock (NVO)
nasdaq.com - July 28 at 10:34 PM
Novo Nordisk A/S (NYSE:NVO) Sets New 1-Year High at $91.18Novo Nordisk A/S (NYSE:NVO) Sets New 1-Year High at $91.18
americanbankingnews.com - July 28 at 11:13 AM
Novo Nordisk A/S (NYSE:NVO) Hits New 12-Month High at $88.90Novo Nordisk A/S (NYSE:NVO) Hits New 12-Month High at $88.90
americanbankingnews.com - July 21 at 12:28 PM
Novo Nordisk A/S (NYSE:NVO) Rating Reiterated by BarclaysNovo Nordisk A/S (NYSE:NVO) Rating Reiterated by Barclays
americanbankingnews.com - July 19 at 4:28 PM
Deutsche Bank Aktiengesellschaft Reaffirms Buy Rating for Novo Nordisk A/S (NYSE:NVO)Deutsche Bank Aktiengesellschaft Reaffirms Buy Rating for Novo Nordisk A/S (NYSE:NVO)
americanbankingnews.com - July 15 at 5:08 PM
Novo Nordisk A/S (NYSE:NVO) Reaches New 52-Week High at $87.81Novo Nordisk A/S (NYSE:NVO) Reaches New 52-Week High at $87.81
americanbankingnews.com - July 15 at 10:43 AM
Novo Nordisk A/S (NYSE:NVO) Given Consensus Rating of "Hold" by AnalystsNovo Nordisk A/S (NYSE:NVO) Given Consensus Rating of "Hold" by Analysts
americanbankingnews.com - July 13 at 1:30 PM
Mid-Morning Market Update: Markets Mostly Higher; Novo Nordisk To Acquire Prothenas ATTR Amyloidosis ProgramMid-Morning Market Update: Markets Mostly Higher; Novo Nordisk To Acquire Prothena's ATTR Amyloidosis Program
markets.businessinsider.com - July 12 at 2:10 PM
Prothena Sells ATTR Amyloidosis Programme To Novo Nordisk For Up To $1.2 Bln - Quick FactsProthena Sells ATTR Amyloidosis Programme To Novo Nordisk For Up To $1.2 Bln - Quick Facts
markets.businessinsider.com - July 12 at 2:10 PM
Prothena Corporation plc: Prothena and Novo Nordisk Announce Acquisition Agreement for Prothenas ATTR Amyloidosis ProgrammeProthena Corporation plc: Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena's ATTR Amyloidosis Programme
finanznachrichten.de - July 12 at 7:42 AM
ABBV vs. NVO: Which Stock Is the Better Value Option?ABBV vs. NVO: Which Stock Is the Better Value Option?
finance.yahoo.com - July 5 at 3:07 PM
Walmart aims to aid in affordable diabetes care with its private brand analog insulinWalmart aims to aid in affordable diabetes care with its private brand analog insulin
finance.yahoo.com - June 29 at 7:06 PM
Now on Sale at Walmart: Insulin That’s Cheaper Than Brands from Lilly, Sanofi, or Novo NordiskNow on Sale at Walmart: Insulin That’s Cheaper Than Brands from Lilly, Sanofi, or Novo Nordisk
finance.yahoo.com - June 29 at 2:05 PM
Walmart to launch lower-priced insulinWalmart to launch lower-priced insulin
finance.yahoo.com - June 29 at 9:05 AM
Walmart launches private label insulin brand at steep discounts for diabetes patientsWalmart launches private label insulin brand at steep discounts for diabetes patients
finance.yahoo.com - June 29 at 9:05 AM
Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trialInvestigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial
finance.yahoo.com - June 26 at 6:58 PM
Heres Why Altimmune Stock Is Surging TodayHere's Why Altimmune Stock Is Surging Today
finance.yahoo.com - June 16 at 3:35 PM
Novo’s Wegovy Approved After Superior Weight-Loss Impact ShownNovo’s Wegovy Approved After Superior Weight-Loss Impact Shown
msn.com - June 7 at 12:07 AM
Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the USWegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US
finance.yahoo.com - June 4 at 5:58 PM
UPDATE 2-U.S. FDA approves Novo Nordisks semaglutide as obesity treatmentUPDATE 2-U.S. FDA approves Novo Nordisk's semaglutide as obesity treatment
finance.yahoo.com - June 4 at 5:58 PM
FDA approves Novo Nordisk’s obesity drug Wegovy, which helped people cut weight 15%FDA approves Novo Nordisk’s obesity drug Wegovy, which helped people cut weight 15%
finance.yahoo.com - June 4 at 5:58 PM
Novo Nordisk (NVO) Inks Deal to Develop Heart Failure TreatmentNovo Nordisk (NVO) Inks Deal to Develop Heart Failure Treatment
finance.yahoo.com - June 1 at 2:15 PM
Novo Nordisk A/S : Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approvalNovo Nordisk A/S : Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval
markets.businessinsider.com - May 29 at 10:10 AM
Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approvalNovo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval
finance.yahoo.com - May 28 at 1:09 PM
Is Novo Nordisk A/S (NVO) A Smart Long-Term Buy?Is Novo Nordisk A/S (NVO) A Smart Long-Term Buy?
finance.yahoo.com - May 28 at 1:09 PM
Trading in Novo Nordisk shares by board members, executives and associated persons on 7 May 2021Trading in Novo Nordisk shares by board members, executives and associated persons on 7 May 2021
finance.yahoo.com - May 7 at 7:11 PM
PFE vs. NVO: Which Stock Should Value Investors Buy Now?PFE vs. NVO: Which Stock Should Value Investors Buy Now?
finance.yahoo.com - May 7 at 2:11 PM
Novo Nordisk (spons ADRs) earnings: heres what to expectNovo Nordisk (spons ADRs) earnings: here's what to expect
markets.businessinsider.com - May 5 at 10:02 PM
Novo Nordisk A/S (NVO) Q1 2021 Earnings Call TranscriptNovo Nordisk A/S (NVO) Q1 2021 Earnings Call Transcript
finance.yahoo.com - May 5 at 10:02 PM
Novo Nordisk A/S: Novo Nordisks net profit increased by 6% in the first three months of 2021Novo Nordisk A/S: Novo Nordisk's net profit increased by 6% in the first three months of 2021
finanznachrichten.de - May 5 at 6:59 AM
Novo Nordisks net profit increased by 6% in the first three months of 2021Novo Nordisk's net profit increased by 6% in the first three months of 2021
finance.yahoo.com - May 5 at 6:59 AM
Novo Nordisk lifts guidance after first quarter beats expectationsNovo Nordisk lifts guidance after first quarter beats expectations
ca.finance.yahoo.com - May 5 at 6:59 AM
Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 29 April 2021Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 29 April 2021
finance.yahoo.com - April 29 at 10:04 AM
Novo Nordisk A/S - Reduction of the share capitalNovo Nordisk A/S - Reduction of the share capital
theglobeandmail.com - April 28 at 12:40 PM
Is NVO Stock A Buy or Sell?Is NVO Stock A Buy or Sell?
finance.yahoo.com - April 24 at 9:58 AM
Novo Nordisk (NVO) to Begin Study on Oral Semaglutide in ObesityNovo Nordisk (NVO) to Begin Study on Oral Semaglutide in Obesity
finance.yahoo.com - April 22 at 11:33 AM
No­vo Nordisk To Start Phase 3 Obe­si­ty Tri­al With Oral Semaglu­tideNo­vo Nordisk To Start Phase 3 Obe­si­ty Tri­al With Oral Semaglu­tide
finance.yahoo.com - April 21 at 5:46 PM
Novo Nordisk to initiate phase 3a development in obesity with oral semaglutideNovo Nordisk to initiate phase 3a development in obesity with oral semaglutide
finance.yahoo.com - April 21 at 12:46 PM
Why Novo Nordisk (NVO) is a Great Dividend Stock Right NowWhy Novo Nordisk (NVO) is a Great Dividend Stock Right Now
finance.yahoo.com - March 30 at 1:37 PM
Novo Nordisk A/S - Articles of AssociationNovo Nordisk A/S - Articles of Association
finance.yahoo.com - March 25 at 1:32 PM
Correction: Resolutions from the Annual General Meeting of Novo Nordisk A/SCorrection: Resolutions from the Annual General Meeting of Novo Nordisk A/S
finance.yahoo.com - March 25 at 1:32 PM
FDA Asks Novo Nordisk For More Information On Semaglutide Label Expansion ApplicationFDA Asks Novo Nordisk For More Information On Semaglutide Label Expansion Application
benzinga.com - March 23 at 10:53 AM
Novo Nordisk : FDA Seeks Additional Data On Type 2 Diabetes Drug SemaglutideNovo Nordisk : FDA Seeks Additional Data On Type 2 Diabetes Drug Semaglutide
nasdaq.com - March 23 at 12:26 AM
Novo Nordisk A/S: Novo Nordisk receives Refusal to File letter for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetesNovo Nordisk A/S: Novo Nordisk receives Refusal to File letter for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
finanznachrichten.de - March 22 at 7:26 PM
Novo Nordisk receives Refusal to File letter for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetesNovo Nordisk receives Refusal to File letter for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
finance.yahoo.com - March 22 at 7:26 PM
Gilead, Novo Nordisk To Test Triple Combo Therapy In New NASH StudyGilead, Novo Nordisk To Test Triple Combo Therapy In New NASH Study
finance.yahoo.com - March 18 at 2:56 PM
Gilead, Novo Nordisk Expand NASH CollaborationGilead, Novo Nordisk Expand NASH Collaboration
finance.yahoo.com - March 18 at 9:55 AM
Does Eli Lilly Have a New Blockbuster Weight Loss Drug?Does Eli Lilly Have a New Blockbuster Weight Loss Drug?
finance.yahoo.com - March 8 at 9:02 AM
This page was last updated on 8/4/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.